Printer Friendly

Actinium Pharmaceuticals names new VP, Head of Clinical Operations.

M2 PHARMA-September 7, 2018-Actinium Pharmaceuticals names new VP, Head of Clinical Operations

(C)2018 M2 COMMUNICATIONS

Actinium Pharmaceuticals Inc (NYSE AMERICAN: ATNM), a clinical-stage biopharmaceutical company, announced yesterday that it has named Robert N Daly, MS, PhD as its new Vice President, Head of Clinical Operations, effective immediately.

Dr Daly will manage all clinical operations, and run a Phase three trial for Iomab-B as a targeted conditioning agent. He will be supervised by Dr Mark Berger, Actinium's Chief Medical Officer, and reports to Actinium's Chairman and CEO, Sandesh Seth.

Dr Daly previously served as Vice President, Clinical at CTI BioPharma, and was Vice President, Development Operations at Durata Therapeutics. He has served as Executive Director, Clinical Operations and Head, Global Medical Sciences and Medical Affairs for Portola Pharmaceuticals Inc.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 7, 2018
Words:140
Previous Article:Accreditation Council for Medical Affairs appoints Charles Stacey to Board of Governors.
Next Article:WuXi AppTec Partner Hutchison MediPharma Receives Approval of Fruquintinib Capsules in China.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters